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KEY MESSAGE
Rats with mild diabetes were used to investigate the usefulness of maternal treatments with idebenone to
prevent post-implantation embryo impairments. A mitochondrial antioxidant maternal treatment prevented
maternal diabetes-induced embryo alterations in prooxidant, proinflammatory and apoptotic markers, and
in the expression of genes involved in mitochondrial biogenesis and function.
A B S T R A C T
Research question: Canmaternal treatments with idebenone, a structural analogue of coenzyme Q10, prevent alterations on markers of proinflammatory–
prooxidant processes, on the expression of genes involved in mitochondrial biogenesis and function, and on the apoptotic rate in embryos from mild
diabetic rats?
Design: A mild diabetic rat model was induced by neonatal–streptozotocin administration (90 mg/kg subcutaneously). Female diabetic rats and con-
trols were mated with healthy males. From day 1 of pregnancy, control and diabetic rats were orally treated with idebenone (100 mg/kg daily). On day
10.5 of gestation, the embryos were explanted and prepared for immunohistochemical studies, for the evaluation of gene expression by reverse tran-
scription polymerase chain reaction and for TdT (terminal deoxynucleotidyl transferase)-mediated dUDP nick-end-labelling assay analysis.
Results: Embryos from mild diabetic rats showed increased levels of nitrated proteins, 4-hydroxynonenal and matrix metalloproteinase 9, which were
prevented by idebenone administration. We also found a decreased embryonic expression of cytochrome c oxidase and reduced mRNA levels of per-
oxisome proliferator activated receptor-γ coactivator-1-α and nuclear respiratory factor-1, both of which were prevented by idebenone administration
to the diabetic pregnant rats. Embryos from mild diabetic rats also showed an increased apoptotic rate, which was diminished by idebenone treatment.
Conclusion: Maternal idebenone treatment ameliorates altered parameters related to the prooxidant–proinflammatory environment found in embryos
from mild diabetic rats, suggesting a putative treatment to prevent diabetes-induced embryo alterations.
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Introduction
In diabetic pregnancies, many molecular and cellular pathways are
altered during embryo development. These alterations are related to
hyperglycaemia and the increase in other intrauterine metabolic sub-
strates, which lead to the generation of a proinflammatory and
prooxidant environment (Eriksson and Wentzel, 2016). During early
organogenesis, the developing embryo is especially susceptible to the
diabetes-induced prooxidant environment caused by the immaturity
of its antioxidant system (Zaken et al., 2000). Increased embryonic
oxidative stress is involved in diabetic-induced teratogenicity, and
further contributes to fetal alterations and the programming of dis-
eases in offspring (Higa and Jawerbaum, 2013; Jawerbaum and White,
2017; Ornoy, 2007; Zabihi and Loeken, 2010; Zhao and Reece, 2013).
Reactive oxygen species mainly originate in the mitochondrion, an
organelle whose function is altered in the development of adult dia-
betic complications (Blake and Trounce, 2014). Cytochrome c oxidase
(COX), the terminal oxidase of the mitochondrial electron transport
chain, catalyzes the final step of electron transfer from reduced cy-
tochrome c to oxygen to make water. It is also one of the three proton
pumps that generate the proton gradient across the inner mitochon-
drial membrane, which powers adenosine triphosphate synthesis. The
transcription of nuclear genes that encode COX subunits is regu-
lated by nuclear respiratory factors 1 and 2 (NRF1 and NRF2) (Dhar
et al., 2008). NRF1 and NRF2 also regulate most nuclear genes in-
volved in mitochondrial biogenesis (mitochondrial transcription factors
A, B1 and B2 [Tfam, Tfb1m and Tfb2m]). In this context, the role of
peroxisome proliferator activated receptor-γ coactivator 1-α (PGC-
1α), which coactivates different transcription factors in response to
energy requirements, is also important to promote the activation of
the transcriptional machinery that regulates mitochondrial biogen-
esis. PGC-1α coactivates NRF1 and NRF2 as well as peroxisome
proliferator activated receptor δ (PPARδ) (Puigserver and Spiegelman,
2003; Scarpulla, 2008; Wang et al., 2003). This is a nuclear receptor
that acts as a nutritional sensor and is able to bind a great variety
of lipid molecules, triggering the transcription of genes involved in
anti-inflammatory, anti-oxidant, metabolic and developmental pro-
cesses (Coll et al., 2010; Rotman et al., 2006). It is the only PPAR isotype
expressed in high levels in the embryo during early organogenesis
(Braissant and Wahli, 1998). In embryos from pregestational
streptozotocin-induced diabetic rats (with maternal glycaemia values
over 350 mg/dl, rat model of severe diabetes), PPARδ expression is
reduced and its ligands ameliorate several altered parameters in dia-
betic embryopathy (Higa et al., 2007, 2012).
Oxidative and nitrative stress have been shown in embryos from
mild and severe experimental models of diabetes (Gareskog et al.,
2006; Jawerbaum and Gonzalez, 2006; Sakamaki et al., 1999; Singh
et al., 2011; Viana et al., 2003). Mitochondrial damage has been found
in embryos from diabetic rats during early organogenesis, although
this is a period characterized by active glycolytic pathways and im-
mature mitochondrial metabolism (Akazawa, 2005; Yang et al., 1995).
Antioxidants have been found to have positive effects on the preven-
tion of experimental diabetic embryopathy (Sakamaki et al., 1999; Viana
et al., 2003). The putative effect of antioxidants with mitochondrial
action, such as idebenone (2-[10-Hydroxydecyl]-5,6-dimethoxy-3-
methyl-1,4-benzoquinone), a structural analogue of coenzyme Q10,
and a potent antioxidant (Carbone et al., 2012; Geromel et al., 2002;
Lin et al., 2015), has never been previously studied. Therefore, in this
study, we used a rat model of mild diabetes (glycaemia values below
250 mg/dl, induced by neonatal streptozotocin administration) to
address the effect of idebenone on markers of inflammatory–
oxidative processes, on the expression of genes involved in
mitochondrial function biogenesis, and on apoptosis in the embryo
during early organogenesis.
Materials and methods
Animals
Albino Wistar rats were bred in the laboratory with free access to com-
mercial rat chow (Asociación Cooperativa Argentina, Buenos Aires,
Argentina) and water, in a lighting cycle of 12 h light–12 h dark. A mild
diabetic rat model was developed by injecting 2-day-old neonates with
streptozotocin (90 mg/kg, subcutaneously, Sigma-Aldrich, St Louis,
MO, USA, diluted in citrate buffer 0.05M pH 4.5, Sigma-Aldrich), as
described previously (Jawerbaum and White, 2010; Martinez et al.,
2012). Because streptozotocin has a short half-life at neutral pH and
selectively enters and accumulates in beta-cells, its cytotoxicity is
largely limited to these cells at the doses we used (Eleazu et al., 2013;
Jawerbaum and White, 2010).
Control rats were injected with citrate buffer only. Glycaemia was
measured with Accu-Chek reagent strips and a glucometer (Bayer
Diagnostics, Buenos Aires, Argentina) and confirmed before mating.
Pregnant rats were fasted for 6 h before glycaemia measurements
were taken on day 10.5 of pregnancy. Rats were considered diabetic
when they presented fasting glucose values higher than 130 mg/dl.
The reproductive characteristics of the diabetic model have been pre-
viously described (Jawerbaum and White, 2010). The animal protocol
was approved on 24 July 2013 by the Institutional Committee for the
Care and Use of Experimental Animals (CICUAL, Resolution CD N°
1497/2013), School of Medicine, University of Buenos Aires, and con-
ducted according to the Guide for the Care and Use of Laboratory
Animals, US National Institutes of Health (NIH Publication, 8th Edition,
2011, http://www.ncbi.nlm.nih.gov/books/NBK54050/?report=reader).
Animal treatment and tissue collection
Control and diabetic female adult rats weremated with untreated adult
males. Mating was confirmed by the presence of sperm in vaginal
smears. The presence of sperm in vaginal smears was used to confirm
mating and to designate day 0.5 of gestation. Animals received treat-
ment with either idebenone (Sigma-Aldrich, 100 mg/kg) or vehicle,
orally from day 0.5–10.5 of gestation.
Animals were killed in a CO2 chamber on day 10.5 of pregnancy,
and the uteri were transferred to Petri dishes with Krebs Ringer Bi-
carbonate solution: 5 mM glucose, 145 mM Na+, 5.9 mM K+, 2.2 mM
Ca+2, 1.2 mMMg+2, 127 mMCl−, 25 mMHCO3−, 1.2 mM SO4−2 and 1.2 mM
PO4−3. The balls of decidual tissue were explanted from each uterus
and gently opened to free the conceptuses, using a stereomicro-
scope and microsurgical dissecting instruments. The embryos were
dissected out of the yolk sacs and evaluated morphologically under
a stereomicroscope. On day 10.5 of pregnancy, the embryos of the
evaluated rats are in the process of neural tube closure, as closure
occurs on day 12 of pregnancy.
Viability was established by the presence of a beating heart. Mal-
formed embryos (3% in the diabetic group) received no further analysis.
Non-malformed viable embryos were further processed according to
protocols described below.
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Analysis of mRNA levels of cox, nrf1, tfam, pparδ and pgc-1α
The mRNA levels of Cox, Nrf1, Tfam, Pparδ and Pgc-1α were evalu-
ated by semi-quantitative reverse transcription polymerase chain
reaction (RT-PCR), as previously described (Higa et al., 2014). Four
pooled embryos from each rat in each experimental group (n = 9) were
kept in RNAlater® (Ambion, Texas, USA) at −20°C and RNA was ex-
tracted with RNAzol (Molecular Research Center, Cincinnati, USA) in
accordance with the manufacturer’s instructions. cDNA was synthe-
sized by incubating 2 µg of extracted RNA in a first-strand buffer
containing Moloney murine leukemia virus (MMLV) enzyme from
Promega (Buenos Aires, Argentina), random primer hexamers
(Promega) and each of all four deoxynucleotide triphosphates
(Invitrogen, San Diego, CA, USA), in accordance with the MMLV manu-
facturer’s instructions (final volume 25 µl). The reaction mixture was
incubated at 37°C for 60 min and then at 70°C for 15 min. cDNA (2 µl,
selected to work within the linear range) was amplified by poly-
merase chain reaction in a buffer containing deoxynucleotide
triphosphates, magnesium chloride solution, Taq polymerase (GoTaq
Polymerase, Promega, Wisconsin, USA) and each specific primer, in
accordance with the Taq polymerase manufacturer’s instructions. The
primers used (Table 1), were purchased from Invitrogen. The primers
for the ribosomal protein L30 were used as an internal control.
The initial step in the reaction was 95°C for 5 min. The following
numbers of cycles are detailed in Table 1. Each cycle consisted of
denaturation at 95°C for 15 s primer annealing at 58°C for 30 s and
extension at 72°C for 15 s. The resulting products were separated on
a 2% agarose gel and stained with SYBR® Safe (Invitrogen). The
images were taken with the ImageQuant image acquiring system and
software (GE Healthcare, Buckinghamshire, UK) and quantified with
the Image J software, National Institutes of Health, Bethesda, MD,
USA.
Immunohistochemical and TUNEL analysis
Immunohistochemistry was carried out to determine levels and lo-
calize 4-hydroxynonenal, nitrotyrosine, matrix metalloproteinase 9
(MMP9) and subunit IV of COX (COXIV) in embryos, as described pre-
viously (Higa et al., 2011). Two embryos from each rat (n = 5) in each
experimental group were explanted, immediately fixed in 4% phos-
phate buffered saline (PBS)-paraformaldehyde and then paraffinized.
The same number of serial, 5-µm sections were captured from each
embryo and on each slide, providing reasonable confidence that protein
localization and quantification were performed on comparable ana-
tomical planes from each embryo. All sections were processed
simultaneously under identical conditions. Sections were deparaffinized
and hydrated in xylene and a series of graded ethanol solutions, fol-
lowed by three washes in PBS and PBS with 0.05% Tween-20 (PBS-
T). Incubation in 0.3% hydrogen peroxide in PBS to block endogenous
peroxidase was carried out for 20 min. Slides were incubated in a hu-
midified chamber overnight with a rabbit anti-4-hydroxynonenal
antibody (1:400 Abcam, Cambridge, UK), rabbit anti-nitrotyrosine an-
tibody (1:4000, Millipore, Temecula, USA), a mouse anti-MMP9 antibody
(1:150, Calbiochem, Billerica, USA) or a rabbit anti-COXIV antibody
(1:300, Abcam). All primary antibodies were checked for antibody speci-
ficity and diluted in PBS-T with 1% bovine serum albumin. Negative
controls were carried out in the absence of primary antibody and by
replacing the primary antibody with a pooled serum of the same
species that contains a spectrum of the Immunoglobulin G sub-
classes (Vector Laboratories Burlingame, CA, USA). Biotinylated horse
anti-mouse antibody, rat adsorbed (1:200 in PBS-T/1.5% normal horse
serum) or biotinylated goat anti-rabbit (1:200 in PBS-T/1.5% normal
goat serum) (Vector Laboratories) was applied, followed by incuba-
tion with an avidin–biotin complex for 60 min (Vector Laboratories).
Staining was visualized by adding 40% 3,3’-diaminobenzidine
tetrahydrochloride chromogen-buffer plus 0.02% (v/v) hydrogen per-
oxide in 0.05 M Tris (pH 7.6) for 10 min. A positive staining appeared
as a dark brown colour. The tissues were then counterstained with
haematoxylin and dehydrated before mounting. Five sections of two
embryos from each rat of each experimental group were examined
by two skilled blinded observers under light microscopy (Nikon Eclipse
E200) and photographed (Nikon DS-Fi1). Immunoreactivity intensity
was quantified using the ImageProPlus software, Media Cybernet-
ics, Bethesda, MD, USA. Data are shown as relative to a value of 1
assigned to the mean value for control. Similar results were ob-
tained using a semiquantitative score (data not shown).
To study apoptosis in embryos, a TdT (terminal deoxynucleotidyl
transferase)-mediated dUTP nick-end-labelling (TUNEL) assay was
carried out using an in-situ cell apoptosis detection kit (DeadEnd Fluo-
rometric TUNEL System, Promega) according to the manufacturer’s
instructions. The sections were examined under fluorescent micros-
copy (Nikon Eclipse E200) and photographed (Nikon DS-Fi1). The
number of positive cells was quantified using the Image J software.
Data are shown as relative to a value of 1 assigned to the mean value
for controls.
Statistical analysis
Data are presented as the mean ± standard error. Groups were com-
pared by two-way analysis of variance in conjunction with Bonferroni’s
test. In all cases, differences were considered statistically signifi-
cant at P < 0.05.
Table 1 – Primer sequences and optimum cycle number for each primer pair used for gene expression analysis by semiquantitative
polymerase chain reaction in rat embryo of 10.5 days of gestation.
Gene Forward primer
(5’ to 3’)
Reverse primer
(5’ to 3’)
Cycles
CoxIVi1 TACGAAACACGACCCCACTG AGCTAGCGACTACGCTTTCC 28
Nrf1 CAACAGGGAAGAAACGGAAA GTGGCTCTGAGTTTCCGAAG 27
Tfam CTGATGGCCATTACATGTGG AAAGCCCGGAAGGTTAG 26
Pparδ GAGGGGTGCAAGGGCTTCTT CACTTGTTGCGGTTCTTCTTCTG 30
Pgc-1α GTGCAGCCAAGACTCTGTATGG GTCCAGGTCATTCACATCAAGTTC 34
L30 CCATCTTGGCGTCTGATCTT GGCGAGGATAACCAATTTC 23
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Results
4-hydroxynonenal, nitrotyrosine and MMP9 levels in embryos
from control and diabetic rats treated or not with idebenone
We first evaluated control and mild diabetic animals treated or not
with idebenone during gestation and found that glycaemia was in-
creased in the diabetic group (control: 101 ± 7 mg/dl; diabetic: 213
± 29 mg/dl, P < 0.001) compared with the control group and that
idebenone treatment was unable to reduce the increased maternal
glucose values (control treated with idebenone: 98 ± 9 mg/dl; dia-
betic treated with idebenone: 207 ± 33 mg/dl). Oxidative stress during
early organogenesis can lead to adverse developmental outcomes and
disease risk later in life. We, therefore, studied 4-hydroxynonenal levels
as a stable product of oxidative-stress induced lipid peroxidation, and
found that its levels were increased in embryos from mild diabetic
rats compared with embryos from control rats (P < 0.001) (Figure 1),
Figure 1 – Effect of maternal idebenone treatment on the levels of 4-hydroxynonenal in embryos from control and diabetic rats on day 10.5
of gestation. (a) A representative photomicrograph of a transverse section from the cephalic zone of the embryo (400X) stained with a
specific anti-4-hydroxynonenal antibody; (b) graphs quantifying the immunohistochemical staining represented in (a). Values are means ±
SEM (n = 5 rats). Two-way analysis of variance in conjunction with Bonferroni’s test was carried out. aP < 0.001 versus control rats not
treated with idebenone; bP < 0.001 versus diabetic rats not treated with idebenone. NT, neural tube.
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and that they were decreased in embryos from diabetic rats
treated with idebenone compared with embryos from non-treated dia-
betic rats (P < 0.001) (Figure 1). We next evaluated nitrotyrosine
immunostaining, a marker of the damage induced by peroxynitrites,
and found that the levels of nitrated proteins in embryos from mild
diabetic rats were increased compared with embryos from control
rats (P < 0.001) (Figure 2), and they were decreased in embryos from
diabetic rats treated with idebenone compared with embryos from
non-treated diabetic rats (P < 0.001) (Figure 2). As peroxynitrites in-
crease the levels and activity of matrix metalloproteinases (MMP)
(Capobianco et al., 2012), we were next interested in studying MMP9
levels, a marker of an inflammatory state when they are in excess.
MMP9 immunostaining was increased in embryos from mild dia-
betic rats compared with embryos from control rats (P < 0.001)
(Figure 3), and were decreased in embryos from both diabetic
(P < 0.001) and control (P < 0.05) rats treated with idebenone com-
pared with embryos from non-treated diabetic and control rats
(Figure 3).
Figure 2 – Effect of maternal idebenone treatment on the levels of nitrated proteins in embryos from control and diabetic rats on day 10.5
of gestation. (a) A representative photomicrograph of a transverse section from the cephalic zone of the embryo (400X) stained with a
specific anti-nitrotyrosine antibody; (b) graphs quantifying the immunohistochemical staining represented in (a). Values are means ± SEM
(n = 5 rats). Two-way analysis of variance in conjunction with Bonferroni’s test was performed. aP < 0.001 versus control rats not treated
with idebenone; bP < 0.001 versus diabetic rats not treated with idebenone NT, neural tube.
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Markers of mitochondrial function and biogenesis in embryos
from control and diabetic rats treated or not with idebenone
With COX, the last component of the mitochondrial respiratory
chain, we found reduced levels in embryos from diabetic rats
compared with embryos from control rats (P < 0.05) (Figure 4), and
increased levels in embryos from both diabetic (P < 0.001) and
control (P < 0.05) rats treated with idebenone (Figure 4) compared
with embryos from non-treated diabetic and control rats. The
subunit IVi1 of COX (COX IVi1) is involved in the regulation of COX
activity. mRNA levels of Cox IVi1 in embryos from diabetic rats were
decreased compared with embryos from control rats (P < 0.05)
(Figure 5a), and increased in embryos from both diabetic (P < 0.05)
and control (P < 0.001) rats treated with idebenone when respec-
tively compared with embryos from non-treated diabetic and control
rats (Figure 5a).
Figure 3 – Effect of maternal idebenone treatment on MMP9 levels in embryos from control and diabetic rats on day 10.5 of gestation. (a) A
representative photomicrograph of a transverse section from the cephalic zone of the embryo (400X) stained with a specific anti-MMP9
antibody; (b) graphs quantifying the immunohistochemical staining represented in (a). Values are means ± SEM (n = 5 rats). Two-way
analysis of variance in conjunction with Bonferroni’s test was performed. aP < 0.05; bP < 0.001 versus control rats not treated with
idebenone; cP < 0.001 versus diabetic rats not treated with idebenone. NT, neural tube.
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We also studied TFAM and NRF1, regulatory proteins involved in
respiratory chain function. Tfam mRNA levels were not different in
embryos from diabetic rats treated or not with idebenone when re-
spectively compared with control rats (Figure 5b). On the other hand,
Nrf1 mRNA levels were reduced in embryos from mild diabetic rats
compared with embryos from control rats (P < 0.05) (Figure 5c), and
increased in embryos from diabetic rats treated with idebenone com-
pared with embryos from non-treated diabetic rats (P < 0.05)
(Figure 5c).
As NRF1 transcription is regulated by PGC-1α, we also studied
this coactivator. Pgc-1αmRNA levels were reduced in embryos from
diabetic rats compared with embryos from control rats (P < 0.05)
(Figure 6a) and increased in embryos from diabetic rats treated with
idebenone compared with embryos from non-treated diabetic rats (P
< 0.05) (Figure 6a).
The nuclear receptor PPARδ is involved in antioxidant and devel-
opmental processes, and is coactivated by PGC-1α. mRNA levels of
Pparδ were also reduced in embryos from mild diabetic rats com-
pared with embryos from control rats (P < 0.05) (Figure 6b) and
increased in embryos from diabetic rats treated with idebenone com-
pared with embryos from non-treated diabetic rats (P < 0.05)
(Figure 6b).
Figure 4 – Effect of maternal idebenone treatment on cytochrome c oxidase (COX) IV levels in embryos from control and diabetic rats on
day 10.5 of gestation. (a) A representative photomicrograph of a transverse section from the cephalic zone of the embryo (400X) stained
with a specific anti-COX IV antibody; (b) graphs quantifying the immunohistochemical staining represented in (a). Values are means ± SEM
(n = 5 rats). Two-way analysis of variance in conjunction with Bonferroni’s test was performed. aP < 0.05 versus control rats not treated
with idebenone; bP < 0.001 versus diabetic rats not treated with idebenone. NT, neural tube.
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Apoptosis in embryos from control and diabetic rats treated
with idebenone
To study the effect of idebenone on apoptosis, we conducted a TUNEL
assay and found that the number of apoptotic cells increased in
embryos from diabetic rats compared with embryos from control rats
(P < 0.001) (Figure 7) and reduced in embryos from diabetic rats treated
with idebenone compared with embryos from non-treated diabetic rats
(P < 0.05) (Figure 7).
Discussion
The main finding of this work was that the antioxidant idebenone can
prevent the increases in markers of prooxidant and proinflammatory
processes in embryos from mild diabetic rats during organogen-
esis. The maternal treatment with idebenone was also able to prevent
the alterations in markers of mitochondrial biogenesis and
function, and cell apoptosis observed in embryos of mild diabetic rats
highlighting the relevance of aberrant mitochondrial pathways in dia-
betic embryopathy and pointing to idebenone as a putative treatment
to ameliorate the development of viable embryos in a prooxidant/
proinflammatory environment.
Importantly, the increased levels of prooxidant and proinflammatory
markers we observed in the embryo from mild diabetic rats during
early organogenesis have also been observed in fetuses (Pustovrh
et al., 2005), placentae (Martinez et al., 2012) and in the postnatal heart
(Capobianco et al., 2015), suggesting that embryonic alterations may
affect later development.
Moreover, we recently found that maternal idebenone adminis-
tration during diabetic pregnancies prevents the programming of
diabetes-induced cardiac alterations in the offspring (Higa et al., 2017).
Idebenone is a synthetic antioxidant that can be orally adminis-
tered. It is found both in the cellular cytosol and inside mitochondria,
and can act as a free-radical scavenger, undergoing reversible re-
duction – oxidation reactions to mediate mitochondrial electron flow
Figure 5 – Effect of maternal idebenone treatment on markers of mitochondrial function and biogenesis in embryos from control and
diabetic rats on day 10.5 of gestation. (a) Cox IVi1 mRNA levels relative to those of L30 in embryos from control and diabetic rats; (b) Tfam
mRNA levels relative to those of L30 in embryos from control and diabetic rats; (c) Nrf1 mRNA levels relative to those of L30 in embryos
from control and diabetic rats. Values are means ± SEM (n = 9 rats). Two-way analysis of variance in conjunction with Bonferroni’s test was
carried out. aP < 0.05; bP < 0.001 versus control rats not treated with idebenone; cP < 0.05 versus diabetic rats not treated with idebenone.
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and thus increase the production of adenosine triphosphate (Carbone
et al., 2012). In this work, idebenone treatment during early organo-
genesis reduced the increased lipid peroxidation associated with mild
diabetes, suggesting that it reduces oxidative stress, and also the in-
creased nitrated proteins, suggesting that it reduces peroxynitrite-
induced damage in embryos from diabetic rats. We have previously
found increased peroxynitrites-induced damage in embryos from
severe diabetic rats (glucose concentrations over 350 mg/dl)
(Jawerbaum et al., 2005), but this is the first time that this damage
is reported in embryos from rats with mild hyperglycaemia (glucose
concentrations below 250 mg/dl). Peroxynitrites are produced by the
reaction between nitric oxide and superoxide and are strong oxidiz-
ing and nitrating species that promote oxidative damage by many
mechanisms (Szabo, 2003). These compounds can increase the pro-
duction and activation of MMP (Capobianco et al., 2012; Sugiura et al.,
2012). We have previously found increased MMP9 levels and activa-
tion in embryos from severe diabetic rats (Higa et al., 2011). In this
work, we also found increased MMP9 levels in the embryos frommild
diabetic rats, which were reduced by idebenone. In pathological con-
ditions, the excess of peroxynitrites can alter the mitochondrial chain
function via the oxidative inactivation of complexes I, II and V and can
also nitrate cytochrome c (Cassina and Radi, 1996; Cassina et al., 2000).
In pathological conditions, peroxynitrites can also increase the Km
for oxygen of COX (Cooper et al., 2003). Maternal diabetes in rats has
been shown to induce alterations in mitochondrial morphology in
embryos from 9 to 11 days of gestation (Yang et al., 1995). In the
present study, by evaluating embryos on day 10.5 of gestation, we found
decreased expression of COX in embryos from diabetic rats, and that
idebenone treatment prevented this alteration, suggesting that, despite
their dependence on glycolytic pathways at the developmental stage
evaluated here, embryos may benefit from idebenone treatment. An
increase in COX expression mediated by idebenone has been previ-
ously seen in the hippocampus and cerebellum of a mouse model of
Angelman syndrome with mitochondrial dysfunction (Llewellyn et al.,
2015). Interestingly, the mechanisms of COX upregulation seem to
depend on upstream regulators, given that the mRNA levels of both
Nrf1 (which regulates COX IV transcription) and its coactivator, Pgc-1
α (Puigserver and Spiegelman, 2003; Scarpulla, 2008), are upregulated
with the maternal idebenone treatment in the embryos from dia-
betic rats. The relevance of maternal idebenone treatment as an
upregulator of Pgc-1α expression in the embryos is supported by
recent findings showing that maternal diabetes induces down-
regulation of Pgc-1α expression in the embryos, changes related to
an increased rate of neural tube defects (Chen et al., 2017).
The nuclear receptor PPARδ participates in cell proliferation and dif-
ferentiation in adult tissue as well as in fetal tissues and has anti-
inflammatory properties (Coll et al., 2010; Rotman et al., 2006). We have
previously found that aberrant PPARδ signalling is involved in embryo
dysmorphogenesis and that PPARδ is reduced in embryos from severe
diabetic rats (Higa et al., 2007, 2014). In the present study, we also found
reduced PparδmRNA levels in the embryos frommild diabetic rats and
that idebenone was able to modulate Pparδ transcription, increasing
the reducedmRNA levels of this nuclear receptor. Although themecha-
nism remains unclear, it has been recently suggested that PPARs are
epigenetically regulated (Lendvai et al., 2016) and that reactive oxygen
species participate in many important epigenetic processes (Afanas’ev,
Figure 6 – Effect of maternal idebenone treatment on key regulators of cell energy homeostasis in embryos from control and diabetic rats
on day 10.5 of gestation. (a) Pgc-1αmRNA levels relative to those of L30 in embryos from control and diabetic rats; (b) PparδmRNA levels
relative to those of L30 in embryos from control and diabetic rats. Values are means ± SEM (n = 9 rats). Two-way analysis of variance in
conjunction with Bonferroni’s test was performed. aP < 0.05 versus control rats not treated with idebenone; bP < 0.05 versus diabetic rats
not treated with idebenone.
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Figure 7 – Effect of maternal idebenone treatment on apoptosis in embryos from diabetic rats on day 10.5 of gestation. a) shows
representative photomicrographs of a transverse section from the cephalic zone of the embryo (400X). Apoptotic cells were labelled in
green and nuclei in red by propidium iodide; b) the number of TdT (terminal deoxynucleotidyl transferase)-mediated dUTP nick-end-
labelling-positive cells is shown. Values are means ± SEM (n = 5 rats). Two-way analysis of variance in conjunction with Bonferroni’s test
was performed. aP < 0.001 versus control rats not treated with idebenone; bP < 0.05 versus diabetic rats not treated with idebenone.
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2015). The upregulation of Pparδ by idebenone observed in the embryos
from diabetic rats may contribute to a decrease in the prooxidant/
proinflammatory environment as PPARs regulate the expression of
antioxidant enzymes and modulate the expression of the inducible
isoform of nitric oxide synthase and MMPs (Barlaka et al., 2015; Chao
et al., 2014). PPARδ is also involved in inhibiting apoptosis in different
tissues (Barlaka et al., 2015; Schuster et al., 2010).
An optimal balance between cell proliferation and apoptosis is re-
quired for proper development. An increased apoptotic rate related
to a prooxidant–proinflammatory environment has been reported in
murine embryos exposed to a diabetic environment (Gareskog et al.,
2007; Wu et al., 2016; Yang et al., 2008). In the present study, idebenone
administration reduced the increased apoptotic rate in embryos from
diabetic rats, probably by increasing PPARδ levels, reducing the
prooxidant–proinflammatory processes, and preventing the altera-
tion in mitochondrial function and biogenesis parameters. As a
limitation, we were not able to measure idebenone levels in the
embryo. Therefore, it is not clear whether the effects of maternal
idebenone treatment on embryos is attributable to a direct effect on
the embryos or to its impact on maternal tissues.
We conclude that oxidative stress is a main inductor of aberrant
pathways in the embryo during early organogenesis and that the use
of an antioxidant that targets mitochondria ameliorates several mi-
tochondrial, nuclear, cytoplasmic and extracellular parameters, thus
precluding embryonic changes associated with maternal diabetes.
Idebenone is currently used in Friedreich’s ataxia, Alzheimer’s disease
and Leber hereditary optic neuropathy disease (Gutzmann andHadler,
1998;Meyerson et al., 2015; Parkinson et al., 2013). Therefore, it would
be interesting to study whether maternal idebenone treatment may
improve diabetes-induced neural alterations in the offspring. As our
data suggest a potential role of idebenone in preventing maternal
diabetes-induced embryo damage, clinical studies are needed to
address thepotential use of this drug in pregestational diabetic patients.
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